Business Description
MindMaze Therapeutics Holding SA
SIC : 2836
ISIN : CH1251125998
Compare
Compare
Traded in other countries / regions
MMTX.SwitzerlandMMTXz.UKV6M.GermanyRLFTY.USA IPO Date
2026-09-10Description
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 221.83 | |||||
Equity-to-Asset | 0.82 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y Total Revenue Growth Rate Estimate | 305.55 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.4 | |||||
Quick Ratio | 1.28 | |||||
Cash Ratio | 0.72 | |||||
Days Inventory | 3234.22 | |||||
Days Sales Outstanding | 208.83 | |||||
Days Payable | 3407.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 89.76 | |||||
Operating Margin % | -1075.07 | |||||
Net Margin % | -1205.88 | |||||
EBITDA Margin % | -654.5 | |||||
FCF Margin % | -1209.66 | |||||
OCF Margin % | -1205.7 | |||||
ROE % | -36.47 | |||||
ROA % | -28.32 | |||||
ROIC % | -28.55 | |||||
ROC (Joel Greenblatt) % | -908.26 | |||||
ROCE % | -24.6 | |||||
Moat Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 3.19 | |||||
PS Ratio | 6.46 | |||||
PB Ratio | 0.74 | |||||
Price-to-Tangible-Book | 15.6 | |||||
EV-to-EBIT | -2.34 | |||||
EV-to-EBITDA | -3.04 | |||||
EV-to-Forward-EBITDA | 0.84 | |||||
EV-to-Revenue | 19.9 | |||||
EV-to-Forward-Revenue | 0.52 | |||||
EV-to-FCF | -1.72 | |||||
| Price-to-Net-Current-Asset-Value | 15.6 | |||||
Earnings Yield (Greenblatt) % | -42.65 | |||||
FCF Yield % | -49.06 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MindMaze Therapeutics Holding SA Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.211 | ||
| EPS (TTM) (€) | -0.095 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | - | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 0.156 - 0.169 | ||
| Shares Outstanding (Mil) | 169.99 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MindMaze Therapeutics Holding SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MindMaze Therapeutics Holding SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
MindMaze Therapeutics Holding SA Frequently Asked Questions
What is MindMaze Therapeutics Holding SA(HAM:V6M)'s stock price today?
The current price of HAM:V6M is €0.16. The 52 week high of HAM:V6M is €0.17 and 52 week low is €0.16.
When is next earnings date of MindMaze Therapeutics Holding SA(HAM:V6M)?
The next earnings date of MindMaze Therapeutics Holding SA(HAM:V6M) is .
Does MindMaze Therapeutics Holding SA(HAM:V6M) pay dividends? If so, how much?
MindMaze Therapeutics Holding SA(HAM:V6M) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers